Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +50

Cardinal Health (CAH) Q3 Earnings Beat Estimates

💰 Cardinal Health reported Q3 earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.80 and beating last year's $2.35 per share.

📈 The quarterly earnings surprise was +13.22%, following a previous quarter that also beat estimates by +10.04%.

✅ Over the trailing four quarters, Cardinal Health has exceeded consensus EPS estimates in four out of four instances.

📉 Revenue for the quarter ended March 2026 came in at $60.94 billion, which missed the Zacks Consensus Estimate by 2.27% despite rising from last year's $54.88 billion.

🔄 Cardinal has exceeded revenue estimates twice over the last four quarters.

⚠️ Analysts note that the sustainability of stock price movement will depend on management commentary during the earnings call.

📉 Cardinal Health shares have underperformed, losing about 1.3% year-to-date compared to the S&P 500's 4.2% gain.

📊 The Zacks Rank for Cardinal is #2 (Buy), driven by favorable estimate revisions and a strong correlation between these trends and near-term stock movements.

🔮 Current consensus estimates project $2.34 EPS and $67.23 billion revenue for the coming quarter, alongside $10.32 EPS and $259.11 billion revenue for the fiscal year.

🏥 Cardinal Health belongs to the Zacks Medical - Dental Supplies industry, which is currently ranked in the top 22% of all industries.

🆚 Peer company Lifevantage (LFVN) has not yet reported its Q3 results, which are expected on May 6 with estimated earnings of $0.16 per share.

⬇️ For Lifevantage, analysts expect revenues of $47.82 million, representing an 18.2% year-over-year decline.

Bullish Signals
  • Cardinal Health reported quarterly earnings of $3.17 per share, surpassing the Zacks Consensus Estimate of $2.8 per share with a positive surprise of +13.22%.
  • The company has exceeded consensus EPS estimates in four out of the last four quarters, demonstrating consistent performance strength.
  • Cardinal currently holds a Zacks Rank #2 (Buy), indicating strong potential to outperform the market in the near future based on favorable earnings estimate revisions.
  • The Medical - Dental Supplies industry ranks in the top 22% of all Zacks industries, positioning Cardinal within a high-performing sector that historically outperforms the bottom half by more than 2 to 1.
  • Year-over-year earnings increased from $2.35 per share to the current $3.17 per share, reflecting robust business growth after adjusting for non-recurring items.
Risk Factors
  • Cardinal Health's quarterly revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.27%, indicating a downward revision in analyst expectations despite an earnings beat.
  • The company's stock price has lost approximately 1.3% since the beginning of the year, significantly underperforming the S&P 500's gain of 4.2% during the same period.
  • Investors face uncertainty regarding future stock performance as the sustainability of recent price movements depends heavily on management's upcoming commentary rather than immediate financial results.
  • A peer competitor in the same industry, Lifevantage (LFVN), reports a significant decline in expected earnings with an EPS of $0.16 representing a -38.5% year-over-year change.
Full Analysis
Cardinal Health (CAH) reported Q3 earnings per share of $3.17, surpassing the Zacks Consensus Estimate of $2.80 and significantly exceeding the year-ago figure of $2.35. The quarterly results reflect a positive earnings surprise of 13.22%, continuing a streak where the company has beaten consensus EPS estimates for four consecutive quarters. However, total revenues for the quarter ended March 2026 were recorded at $60.94 billion, which missed the consensus estimate by 2.27%. Despite this revenue miss, the stock remains in a positive technical setup according to Zacks analysis, maintaining a Zacks Rank of #2 (Buy) due to favorable earnings estimate revisions ahead of the release. Analysts note that while Cardinal has underperformed the broader market with shares down approximately 1.3% versus the S&P 500's gain of 4.2% since the start of the year, the company's immediate price trajectory is likely to depend on management's commentary during the earnings call. The current consensus outlook projects $10.32 per share for the fiscal year and $2.34 for the upcoming quarter against projected revenues of $259.11 billion and $67.23 billion respectively. Furthermore, the company operates in the Medical - Dental Supplies industry, which currently ranks in the top 22% among all Zacks industries, suggesting a positive sector-wide performance potential that typically drives better returns than the bottom half of sectors. The article concludes by highlighting the importance of tracking earnings estimate revisions as a reliable metric for predicting short-term stock movements. While Cardinal Health reported its figures, the text also briefly mentions peers like Lifevantage (LFVN), which has yet to report results but is expected to show a significant decline in earnings and revenue in the upcoming quarter. Overall, the report frames Cardinal Health as a stock with strong recent earnings momentum supported by a solid industry rank and positive consensus trends, despite the minor revenue shortfall in the latest quarter.